RT Journal
T1 Error in financial disclosure in: Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2009
FD February 9
VO 169
IS 3
SP 304
OP 304
DO 10.1001/archinternmed.2008.614
UL http://dx.doi.org/10.1001/archinternmed.2008.614
AB 
“Financial Disclosure: Dr Keitel has received research support from Protein Sciences Inc and Novartis Vaccines. Dr Nichol has served as a consultant for the influenza vaccine manufacturers sanofi pasteur, GlaxoSmithKline Biologicals, CSL Biotherapies, Novartis, and MedImmune and has received research funding from sanofi pasteur and GlaxoSmithKline Biologicals. Dr Treanor has received research support from Protein Sciences, Merck, Wyeth, GlaxoSmithKline, Antigen Express, Mercia Pharma, VaxInnate, Ligocyte, Sanofi, and CSL Biotherapies; has served as a consultant/scientific advisory board member for AlphaVax, Epimmune, Dynavax, Immune Targeting Systems, Pulmatrix, Powdermed, PaxVax, and Toyama; and has served as a Data Safety Monitoring Board member for Medimmune and Novavax.”